The European Commission said Wednesday that it had given formal approval for Leqembi, a long-awaited new treatment for ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

Raw material dependency and transport bottlenecks, not just production capacity, are the key challenges facing the EU's radiopharmaceutical sector, according to the European Medicines Agency (EMA). Vi ...

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety ...

More ‘biosimilar’ medicines should be brought to market in the EU because of a regulatory policy shift on the need to carry ...

Weight loss drugs such as semaglutide, found in Ozempic and Wegovy, are tied to a 40% reduced risk of an Alzheimer's disease diagnosis. On Wednesday, a study in Nature suggested that a vaccine for ...

The natural gas market continues to hang around the crucial 200 Day EMA on Wednesday, as we are trying to price in the idea of a rollover into warmer temperatures in the United States and Europe. With ...

At present, the use of NAMs in regulatory submissions to the European Medicines Agency (EMA) is limited. This is owing to barriers such as developers' caution in sharing NAM data with regulators ...

European Medicines Agency (EMA), on clinical studies involving the company’s gene therapy Elevidys. In a letter to the patient advocacy group World Duchenne Organization on Monday, Roche (OTCQX ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...

The natural gas market continues to see a bit of selling pressure, as the market is now hanging about the crucial 200 Day EMA ...

The EMA is implementing major changes to accelerate drug approvals in the EU, addressing delays that affect patients and businesses alike. Following a turbulent period marked by Brexit and the ...